Camurus AB (publ) (CAMRF)
USD 50.97
(0.0%)
USD 50.97
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 564.56 Million SEK | 600.23% |
| 2022 | 80.62 Million SEK | 182.51% |
| 2021 | -97.72 Million SEK | 49.49% |
| 2020 | -193.48 Million SEK | 44.87% |
| 2019 | -350.96 Million SEK | -24.19% |
| 2018 | -282.59 Million SEK | -18.11% |
| 2017 | -239.26 Million SEK | -142.09% |
| 2016 | -98.83 Million SEK | 50.72% |
| 2015 | -200.55 Million SEK | -412.68% |
| 2014 | 64.14 Million SEK | -49.97% |
| 2013 | 128.2 Million SEK | 558.97% |
| 2012 | 19.45 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 88.59 Million SEK | 7.24% |
| 2024 Q1 | 100.83 Million SEK | 688.24% |
| 2023 Q3 | 113.63 Million SEK | -70.43% |
| 2023 FY | - SEK | 600.23% |
| 2023 Q4 | -13.83 Million SEK | -112.17% |
| 2023 Q2 | 384.31 Million SEK | 377.75% |
| 2023 Q1 | 80.44 Million SEK | 224.77% |
| 2022 Q1 | 7.97 Million SEK | 153.71% |
| 2022 FY | - SEK | 182.51% |
| 2022 Q3 | 44.75 Million SEK | 343.32% |
| 2022 Q4 | 24.76 Million SEK | -44.65% |
| 2022 Q2 | 10.09 Million SEK | 26.66% |
| 2021 Q3 | -2.88 Million SEK | 94.92% |
| 2021 Q4 | -14.83 Million SEK | -415.24% |
| 2021 FY | - SEK | 49.49% |
| 2021 Q1 | -23.29 Million SEK | 70.31% |
| 2021 Q2 | -56.7 Million SEK | -143.42% |
| 2020 Q1 | -74.4 Million SEK | 13.41% |
| 2020 FY | - SEK | 44.87% |
| 2020 Q4 | -78.46 Million SEK | -293.48% |
| 2020 Q3 | -19.94 Million SEK | 3.59% |
| 2020 Q2 | -20.68 Million SEK | 72.2% |
| 2019 Q4 | -85.92 Million SEK | -14.33% |
| 2019 Q1 | -82.25 Million SEK | 19.34% |
| 2019 Q2 | -107.62 Million SEK | -30.85% |
| 2019 Q3 | -75.16 Million SEK | 30.16% |
| 2019 FY | - SEK | -24.19% |
| 2018 Q2 | -80.04 Million SEK | -76.53% |
| 2018 FY | - SEK | -18.11% |
| 2018 Q4 | -101.96 Million SEK | -80.78% |
| 2018 Q3 | -56.4 Million SEK | 29.53% |
| 2018 Q1 | -45.34 Million SEK | 30.24% |
| 2017 FY | - SEK | -142.09% |
| 2017 Q3 | -65.99 Million SEK | -14.38% |
| 2017 Q4 | -64.99 Million SEK | 1.52% |
| 2017 Q1 | -50.57 Million SEK | -47.86% |
| 2017 Q2 | -57.69 Million SEK | -14.08% |
| 2016 Q1 | -24.01 Million SEK | 39.12% |
| 2016 FY | - SEK | 50.72% |
| 2016 Q3 | -15.58 Million SEK | 37.74% |
| 2016 Q4 | -34.2 Million SEK | -119.5% |
| 2016 Q2 | -25.03 Million SEK | -4.22% |
| 2015 Q2 | -146.79 Million SEK | -1151.89% |
| 2015 Q1 | 13.95 Million SEK | -85.63% |
| 2015 Q3 | -28.26 Million SEK | 80.75% |
| 2015 Q4 | -39.45 Million SEK | -39.59% |
| 2015 FY | - SEK | -412.68% |
| 2014 Q4 | 97.12 Million SEK | 6170.0% |
| 2014 Q3 | -1.6 Million SEK | 0.0% |
| 2014 FY | - SEK | -49.97% |
| 2013 FY | - SEK | 558.97% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 894.76% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 9622.258% |
| SQZ Biotechnologies Company | -64.14 Million USD | 980.195% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 3350.236% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | -500.359% |
| Mesoblast Limited | -62.38 Million USD | 1004.902% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 36854.426% |
| Genus plc | 73.7 Million USD | -666.033% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 8639.13% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 16016.727% |
| Marizyme, Inc. | -34.28 Million USD | 1746.855% |
| ContraFect Corporation | -64.99 Million USD | 968.576% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 6536.001% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 12573.303% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 40374.132% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 21449.106% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 24394.739% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 109079.898% |
| Accustem Sciences Inc. | -3.74 Million USD | 15169.484% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 1270.643% |
| EV Biologics, Inc. | -1.26 Million USD | 44654.632% |
| Q BioMed Inc. | -617.62 Thousand USD | 91508.744% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -15705.319% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 89372.714% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 24813.01% |
| Biomind Labs Inc. | -1.03 Million USD | 54671.219% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | -5615.966% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 7983.596% |
| Skye Bioscience, Inc. | -13.54 Million USD | 4267.292% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 38056.262% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 2258364.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 14634.487% |
| IMV Inc. | -35.52 Million USD | 1689.279% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 3657.501% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 22664.931% |
| GB Sciences, Inc. | -1.41 Million USD | 39861.389% |
| Alpha Cognition Inc. | -9.7 Million USD | 5916.909% |
| HST Global, Inc. | -5303.00 USD | 10646262.55% |
| CSL Limited | 4.78 Billion USD | 88.211% |
| Halberd Corporation | -74.27 Thousand USD | 760161.39% |
| Enzolytics Inc. | -2.12 Million USD | 26705.009% |
| Resverlogix Corp. | -11.74 Million USD | 4908.091% |
| Affymax, Inc. | -14.29 Million USD | 4049.395% |
| SYBLEU INC | -141.57 Thousand USD | 398886.475% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 18531.703% |
| argenx SE | -216.02 Million USD | 361.345% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 1120.196% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -46289.975% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 37765.204% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -148923.345% |
| AVAX Technologies, Inc. | -6.11 Million USD | 9336.038% |
| Zenith Capital Corp. | -8.6 Million USD | 6660.144% |
| Genscript Biotech Corporation | -248.71 Million USD | 326.989% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 3240820.969% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 23176.844% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 320831.744% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 1524.346% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 19619.446% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 54057.711% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -8396181.975% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 32360.933% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 29490.534% |
| BioStem Technologies, Inc. | -7.55 Million USD | 7574.087% |
| ONE Bio Corp. | 13.61 Million USD | -4047.243% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 311863.342% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 27546.087% |
| Agentix Corp. | -1.37 Million USD | 41256.445% |
| LadRx Corporation | 412.28 Thousand USD | -136836.522% |
| Cell Source, Inc. | -4.27 Million USD | 13313.869% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 153840.118% |
| Regen BioPharma, Inc. | 1.46 Million USD | -38411.797% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 60355.788% |
| NovAccess Global Inc. | -1.03 Million USD | 54658.14% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -6276.538% |
| Itoco Inc. | -1.86 Million USD | 30306.929% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 148818.719% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 50688.351% |
| Kadimastem Ltd | -2.62 Million USD | 21612.349% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 236171.921% |
| CytoDyn Inc. | -18.02 Million USD | 3231.433% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 714478.266% |
| Mobile Lads Corp. | -2.24 Million USD | 25290.805% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 4616716.24% |
| Qrons Inc. | -40.08 Thousand USD | 1408662.661% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 116342.86% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -106940.326% |
| Rebus Holdings, Inc. | -951 Thousand USD | 59465.51% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 53260.14% |
| International Stem Cell Corporation | 202 Thousand USD | -279388.119% |
| Bioxytran, Inc. | -3.82 Million USD | 14878.646% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 1072603.799% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 23031.828% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 1673.966% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 1254691.111% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 20719.649% |
| Neutra Corp. | -181.24 Thousand USD | 311589.845% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 2900.566% |
| PureTech Health plc | -11.62 Million USD | 4955.646% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 2900.758% |
| IXICO plc | -707 Thousand USD | 79953.748% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 7446.337% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 1267.762% |
| CSL Limited | 4.73 Billion USD | 88.072% |
| Cellectis S.A. | -92.63 Million USD | 709.446% |